**Name of Journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 19110**

**Manuscript Type: Topic Highlights**

**2015 Advances in Inflammatory Bowel Disease**

**Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease**

Marín AC *et al*. Vaccination in IBD

Alicia C Marín, Javier P Gisbert, María Chaparro

**Alicia C Marín, Javier P Gisbert, María Chaparro,** Gastroenterology Unit, Hospital Universitario de La Princesa and Instituto de Investigación Sanitaria Princesa, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, 28021 Madrid, Spain

**Author contributions:** Chaparro M selected the content of the review; Chaparro M and Gisbert JP reviewed the literature on immunogenicity of vaccines in patients with inflammatory bowel disease; and Marin AC reviewed articles related to mechanisms of response to vaccination; all the authors contributed to the drafting of the manuscript.

**Conflict-of-interest statement:** Gisbert JP and Chaparro M have served as speakers, consultants, and advisory board members for and have received research funding from MSD and AbbVie. AC Marín: none.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: María Chaparro, MD, PhD,** Gastroenterology Unit, Hospital Universitario de La Princesa and Instituto de Investigación Sanitaria Princesa, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Americio 17 portal E 2ºC, 28021 Madrid, Spain. mariachs2005@gmail.com

**Telephone:** +34-91-3093911

**Fax:** +34-91-4022299

**Received:** April 29, 2015

**Peer-review started:** May 12, 2015

**First decision:** June 2, 2015

**Revised:** June 23, 2015

**Accepted:** August 30, 2015

**Article in press:**

**Published online:**

**Abstract**

Inflammatory bowel disease is an immunological disorder usually treated with immunosuppressive therapy, what can lead to a vulnerability to infections. Although many infections can be prevented by vaccination, vaccination coverage in these patients in clinical practice is insufficient. Therefore, the seroprotection condition should be verified, even for routine vaccines such as hepatitis B or pneumococcus. Response to vaccines in inflammatory bowel disease (IBD) patients is thought to be impaired owing to the immunological alterations generated by the disease and also to the immunomodulatory treatments. The immunogenicity of hepatitis B, influenza, and pneumococcal vaccines is impaired in IBD patients, whereas the response to papillomavirus vaccine seems similar to that observed in the healthy population. On the other hand, data on the immunogenicity of tetanus vaccine in IBD patients are conflicting. Studies assessing the response to measles-mumps-rubella, varicella, and herpes zoster vaccines in IBD patients are scarce. The cellular and molecular mechanisms responsible for the impairment of the response to vaccination in IBD patients are poorly understood. Studies aiming to assess the response to vaccines in IBD patients and to identify the mechanisms involved in their immunogenicity are warranted. A better understanding of the immune response, specifically to vaccine, in patients with immune-mediated diseases (such as IBD), is crucial when developing vaccines that trigger more potent immunologic responses.

**Key words:** Crohn’s disease; Ulcerative colitis; Inflammatory bowel disease; Tumor necrosis factor; Vaccine; Vaccination; Immunogenicity

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Inflammatory bowel disease (IBD) patients are vulnerable to infections owing to the underlying immunological disorder and to the immunosuppressive therapy used to treat the disease. Although some of these infections could be vaccine-preventable, IBD patients show impaired immunogenicity to some vaccines (such as hepatitis B or pneumococcal vaccines). In this review, the authors discuss available data on the immunogenicity of vaccines in IBD patients and summarize current knowledge on the mechanisms that could impair the response to the vaccines.

Marín AC, Gisbert JP, Chaparro M. Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease. *World J Gastroenterol* 2015; In press

**INTRODUCTION**

Crohn’s disease and ulcerative colitis are the main two inflammatory bowel diseases (IBD). Treatment during the last decade has been based on immunosuppressants and biological therapies, such as anti-tumor necrosis factor-α (TNF) agents[1]. Immunosuppressants and biologics are used increasingly often and earlier during the course of the disease[1]. In this respect, patients with IBD are vulnerable to infections owing to the immunological disorder caused by the disease itself or to the immunosuppression induced by the treatments.

Prevention of infectious diseases is a major issue for public health, and vaccination has shown to be one of the most successful strategies against the spread of several diseases. Accordingly, the European Crohn’s and Colitis Organisation (ECCO) suggests to know the seroprotection condition of IBD patients, even for routine vaccines such as hepatitis B or pneumococcus[2] (tables 1 and 2). Although numerous groups and experts support the importance of adequate vaccination of IBD patients, the percentage of physicians that monitor and routinely recommend the administration of vaccines to IBD patients is low (approximately 50%)[3-5].

Some studies have suggested that the response to vaccines in IBD patients is impaired[6-10]. The disease-related immune disorder and the immunosuppression induced by the medications could compromise the natural response to immunization and impact the immunogenicity and safety of vaccination in this particular population.

The present review will focus on the immunogenicity of vaccines in patients suffering of IBD and the mechanisms that are potentially involved in impaired response to vaccines.

**INACTIVATED VACCINES**

***Hepatitis B virus vaccination***

The prevalence of hepatitis B infection (HBV) does not significantly differ between the background population and patients with IBD[11]. However, reactivation of HBV may have fatal consequences in immunosuppressed patients. In this respect, the authors of the REPENTINA 2 study observed that among 25 patients with hepatitis B surface antigen (HBsAg), 9 experienced liver dysfunction and 6 liver failure[12]. Thus, active preventive measures such as administration of antiviral drugs to patients with chronic infection and vaccination of seronegative patients are recommended[2].

Recombinant HBV vaccines mainly consist of HBsAg associated with adjuvants that enhance the immune response (*e.g.*, monophosphoryl lipid A, aluminium hydroxide, oil-in-water emulsions). Studies in healthy individuals showed that three doses of HVB vaccine were enough to develop protective anti-HBs antibody titers in over a 95% of the population[13-15]. However, the immunogenicity of this vaccine in IBD patients has proven to be lower, mainly in those patients receiving biologic therapy or immunosuppressants[16,17]. For example, Melmed *et al*[18] detected anti-HBs antibodies in only 3 out of 9 patients, and Vida *et al*[19] in 36% of the vaccinees. In another study with a single-dose vaccine at 0, 1 and 6 mo, an appropiate immune response (*i.e.*, > 10 IU/l) was obtained in all healthy controls but only a 76% of patients were able to reach that cutoff[6].

The largest study to date on HBV vaccination in IBD patients was performed by Gisbert *et al*[20]. A total of 241 patients were vaccinated against HBV with a quick schedule (0, 1 and 2 months) and a double-dose protocol. A 59% and a 39% of the patients developed, respectively, anti-HBs titers > 10 IU/l and > 100 IU/l two months after the last dose. In this study, older age and anti-TNF treatment were associated with a lower response rate.

These findings were confirmed by Loras *et al*[21], who studied 254 patients (235 with anti-HBs < 10 IU/l and 19 with anti-HBs from 10 to 100 IU/l). In this study, only a 26% of patients achieved anti-HBs titers > 100 IU/l. Age ≤ 30 years and starting the vaccination schedule simultaneously with anti-TNF treatment (*vs* months to several years of anti-TNF treatment) were the only predictors of effective vaccination.

The second ECCO consensus on opportunistic infections suggested that the development of seroprotection might require higher doses of the VHB immunogen[2]. The benefit for vaccinating with a high-dose protocol was demonstrated by Gisbert *et al*[22], who studied 148 patients vaccinated against HBV using 2 different protocols: 54% with the “clinical practice” protocol (single doses of Engerix-B® at 0, 1 and 6 mo) and 46% with a faster, double-dose protocol (double doses of Engerix-B® at 0, 1 and 2 months). A higher effective response to vaccination (defined as anti-HBs > 10 IU/L) was reached with the faster double-dose schedule than the response obtained with the single-dose protocol (75% *vs* 41%). The doble-dose protocol was the only factor associated with a better response to the vaccines, suggesting that the faster double-dose schedule could be a suitable option in patients with IBD[22].

Although the double-dose regimen was more immunogenic than the standard dose, IBD patients still showed too low responses to HBV vaccine compared to the healthy controls. Chaparro *et al*[23] assessed the immunogenicity of a recombinant vaccine with a new adjuvant, Fendrix®, compared with double dose Engerix® at 0, 1, 2 and 6 mo in IBD patients. A 4-dose vaccine schedule significantly increased (by > 40%) the response compared with the 3-dose regimen. Older age and treatment with immunosuppressants or anti-TNF drugs impaired the success of the vaccines.

Therefore, despite the numerous attempts to enhance the response to HBV vaccines either by increasing the dosage, optimizing the administration schedule, or testing potent new adjuvants, the response rate to HBV vaccine in IBD patients is still impaired.

The success of the recombinant HBV vaccine depends mainly on the T-cell response to the antigen. However, before such a response can occur, antigen-presenting cells must be able to present the antigen to the T cells, and B cells must be able to proliferate and differentiate into anti-HBs–secreting plasma cells. Thus, the development of protection against HBV will largely depend on the ability of the immune system to produce anti-HBs antibodies. Nevertheless, long-term protection against infection may also require generation of immune memory cells (B and T memory lymphocytes)[24].

The response to HBV vaccine does not only depend on the type and dosage of HBV vaccine. Vaccinee characteristics such as age, gender, the presence of certain genetic polymorphisms, comorbidity, immune status or smoking habit also affect the immunogenicity of the HBV vaccine[25].

Many studies have investigated the immune mechanisms associated with the responsiveness to HBV vaccine in the healthy population. For example, an association between HLA haplotypes and defects in the presentation of HBsAg (by antigen-presenting cells) and recognition HBsAg (by T lymphocytes, affecting their cytokine production profile) has been described[26]. The role of lymphocytes in triggering the immune response has also been investigated, and defects in the lymphocyte repertoire or functionality have been documented[27-29], as has the presence of T-cell populations that suppress the cellular response to HBsAg[30] and abnormal regulatory T-cell counts[31]. Finally, diminished activation of NK and NKT cells has also been associated with a poorer response to this vaccine[32].

Immune-mediated or chronic viral diseases such as HIV infection and chronic liver or kidney disease have also been associated with an impaired response to HBV vaccine. For example, it has been suggested that one of the main reasons for vaccine failure in patients with chronic viral infections (HIV, HCV) is the limited proliferative potential of the lymphocyte associated with changes (induced by the infective virus) in the signaling immune mechanisms[33]. Furthermore, an impaired T-helper response has been reported in patients on dialysis[34]. On the other hand, biological parameters such as higher helper T-CD4 prevaccination counts in HIV-infected patients[35] or a higher CD4/CD8 ratio in dialysis patients[36] have been shown to predict a better response to vaccination.

In IBD patients, data on the cellular or molecular mechanisms impairing the immunogenicity of HBV vaccine are scarce. Several of the genetic mutations and polymorphisms associated with an increased risk of developing IBD have also been involved in recognition of intestinal microbiota by the innate immune system (*NOD2, TLR4*), in autophagy (*ATG16L1, IRGM, VAMP3*), in intestinal barrier function (*DLG5, MUC1*), and in the activation, survival and growth of lymphocytes (*HLA, IL23R, IL10, IL10R, IL2RA, ERAP2, CPEB4, TNFSF11, SMAD3*)[37,38]. The genetic and immunological peculiarities of patients with IBD described above, together with the effect of the immunomodulatory therapies, could therefore affect the ability of the immune system to react properly to the vaccine antigens.

***Human papillomavirus vaccination***

Human papillomavirusinfection(HPV) is a sexually transmitted disease that comprises some 40 oncogenic variants classed as low to high-risk to develop an anogenical neoplasm[39-41]. As HPV-associated tumors may be more common after prolonged immunosuppressive therapy[2], vaccination has been recommended in patients with HPV infection[41].

Since 2006, a quadrivalent vaccine that covers types HPV-6, -11, -16 and -18, is accesible in Europe . Since 2007, also a bivalent vaccine for types HPV-16 and -18 was authorized. Both prophylactic vaccines are effective and safe against HPV in the immunocompetent population (95%-100%)[42,43].

Jacobson *et al*[44] assessed the immunogenicity and tolerability of the quadrivalent HPV vaccine in IBD patients receiving immunosuppressive therapies and in healthy controls. The study included 33 IBD patients who received 3 doses of Gardasil® at 0, 2 and 6 mo. After the 3 doses, a 94% of the patients seroconverted to the four subtypes of HPV, and only a 6% were not seropositive to type HPV-18. This figure was similar to that described in healthy individuals. Unfortunately, owing to the small sample size, the study did not provide data on differences in immunogenicity between the different drug doses (immunomodulators *vs* anti-TNF agents).

***Influenza virus vaccination***

Influenza is a seasonal respiratory disease that, despite its usual acute and self-limiting behaviour, leads to many thousands of visits to emergency departments and can be lethal[8,45,46]. Rates of morbidity and complications have been reported to be higher among immunosuppressed patients[47,48].

The A and B types of the virus are responsible of the human influenza epidemics. Immunosuppression increases the risk of infection, and therefore the annual vaccination for patients on immunosuppressants has been proposed[2]. Whereas the majority of patients suffering IBD will receive immunosuppressive therapy during the course of their disease, the ECCOconsensusrecommends annual vaccination since the disease was diagnosed[2].

There is a live-attenuated influenza vaccine, and also an inactivated type. The live-attenuated ones is not recommended for patients on immunomodulators, but the trivalent inactivated influenza vaccine is not contraindicated in patients on immunosuppressants[49].

Influenza vaccine seems to be less immunogenic in IBD patients, especially evidenced by a low serologic responses against the virus type B[7,8,50,51]. For example, Mamula *et al*[7] included 51 children with IBD and 29 healthy controls and found a significantly poorer immune response in patients than in healthy controls. Furthermore, patients receiving infliximab and immunomodulators were less likely to respond to influenza vaccine antigens. These results were also confirmed by deBruyn *et al*[8] in a study that included 60 children with IBD and 53 healthy controls who received inactivated influenza vaccines including both type A (H1N1 and H3N2) and type B. In this study, children with IBD showed a diminished response to the B component (53%) compare to healthy persons (81%).

The negative effect of immunosuppression on the response to the influenza vaccine has been assessed in several diseases. For example, Cowan *et al*[52] observed lower immunogenicity of the vaccine in immunosuppressed kidney recipients than in healthy people; this diminished response seemed to be associated with a defective humoral and cellular response and with suppression of differentiation of B cells into IgG-secreting plasma cells supported by immunosuppressive therapy. A recent study by Balint *et al*[53] showed that the administration of the vaccine in IBD patients (74% of whom were receiving immunosuppressive therapy) induced a decrease in serum IL-2 levels. Other immune-mediated and chronic viral diseases, such as rheumatoid arthritis, HIV, and common variable immunodeficiency, have been associated with an impaired immune response to the influenza vaccine, thus highlighting the importance of vaccinee immune status.

Genetic polymorphisms have also been associated with the response to influenza vaccination[54].

In conclusion, despite the fact that the response to influenza vaccine appears to be diminished in IBD patients taking immunosuppressant drugs, the degree of response reached in most cases seems to be enough, so it is recommendable the annual influenza vaccination[12].

***Pneumococcal vaccination***

*Streptococcus pneumoniae* is a pathological microorganism able to cause serious infections such as meningitis or pneumonia. Cohort studies have shown that one of the most prevalent infections in immunosuppressed patients with IBD is bacterial pneumonia[55], remaining these patients at high risk of invasive pneumococcal disease[16,18]. Accordingly, it is recommended to administer, at least, 1 dose of the pneumococcal vaccine to all IBD patients[2].

Two types of pneumococcal vaccine are available: the 23-valent polysaccharide vaccine and conjugate vaccines (polysaccharides conjugated to proteins, such as diphtheria and tetanus toxoids, meningococcal outer membrane protein complex or protein D of *Haemophilus influenzae*). Both types of vaccines can be used in IBD patients, but most studies have focused on the 23-valent polysaccharide vaccine.

The immunogenicity of pneumococcal polysaccharide vaccination has been assessed in IBD patients. Study results suggested that IBD patients receiving immunosuppressants have significantly impaired postvaccination titers, while not immunosuppressed patients and healthy people have similar response rates. Moreover, patients on combination therapy (*i.e.*, taking more than one immunosuppressant) had a lesser immune response to the pneumococcal vaccine than patients treated with only one immunosuppressive drug in monotherapy[9,10,55]. As these data reflects that, somehow, immunosuppressant influences the outcome of the 23-valent pneumococcal vaccine, it is advisable to administer the vaccine at diagnosis or at least 2 wk before starting any immunomodulatory treatment[13, 55]. A booster dose should be administered after 5 years[2]. Despite the suboptimal response to vaccination among IBD patients receiving immunomodulators or biological drugs, the vaccine could still confer some degree of protection[3].

Pneumococcal 23-valent vaccine is composed of polysaccharides that are T-cell–independent antigens, which do not induce immunologic memory. B lymphocytes are responsible for recognizing polysaccharides and secreting protective antibodies against pneumococcal bacteria (IgG and IgM). The phenotype of the B cells that react specifically against the 23-valent vaccine has not been fully identified, although, at least in young healthy people, most seem to be IgM+ memory B cells[56]. In elderly people, however, the response to the 23-valent vaccine was mediated by switched memory B cells (IgM-) instead of IgM+ memory B cells[57]. This “alternative” immunological mechanism that generates protection through switched memory B cells was also associated with decreased opsonophagocytic activity[57]. People with low counts of IgM+ memory B cells (*e.g.*, the elderly or patients with common variable immunodeficiency) show diminished efficacy of pneumococcal vaccine and increased susceptibility to infections caused by encapsulated bacteria, such as *S. pneumoniae*[58,59]. Notably, IBD patients, even those who are not receiving immunomodulators, also have a lower proportion of circulating IgM+ memory B cells than healthy controls, probably owing to deficient spleen function[60,61].

Other studies that have investigated the relevance of switched memory B cells in IBD patients have shown conflicting results. Di Sabatino *et al*[60] compared the percentage of circulating switched memory B cells between patients with IBD and healthy adults and found no significant differences. In contrast, Fallahi *et al.* found fewer switched memory B cells in children with Crohn’s disease (but not in those with ulcerative colitis) than in healthy young adults vaccinated with a nonconjugate pneumococcal vaccine[62].

An increase in the proportion of IgM+ memory B cells has been observed in IBD patients who respond to anti-TNF drugs[63]. This finding has been confirmed in patients with spondyloarthritis receiving anti-TNF therapy[64]. To the best of our knowledge, no study has assessed the possible relation between switched/unswitched memory B-cell counts, opsonization activity, use of immunosuppressants, and response to pneumococcal vaccine in IBD patients.

In contrast with vaccines that include only polysaccharides, conjugate pneumococcal vaccines have the advantage of inducing both humoral response and immune memory. However, despite their potential benefits in IBD patients, conjugate pneumococcal vaccines been poorly studied.

***Tetanus***

Patients with IBD not vaccinated against tetanus or with unknown vaccination status should receive the primary series of tetanus vaccines (3 doses). After the initial series, all patients should receive the booster every 10 years. Three studies have investigated the serological response to the booster vaccine in IBD patients, and found conflicting results: 2 studies suggested an altered response[65,66], while the third observed normal anti-tetanus antibody titers[67]. Brogan *et al*[65] suggested that the impaired response to tetanus vaccine in IBD patients could be caused by a defect in the development of IgG-secreting plasma cells; however, this finding has not been confirmed elsewhere.

**LIVE-ATTENUATED VACCINES**

***Measles, mumps and rubella***

Since the vaccine against measles, mumps and rubella is commonly administered in the childhood, it is usually given before IBD is diagnosed. Vaccine can be administered in IBD patients not treated with immunosuppressant drugs and lacking of immunity. Nevertheless, as this vaccine is generally given in most developed countries, the risk of acquisition of these infections is very low[68].

***Varicella and herpes zoster vaccinations***

Varicella infection is generally a mild disease in children but it can develop severe complications, especially in adults, leading to the death in 20/100000 persons[69]. Immunity to varicella is usually acquired through infection in the childhood[18]; however, as this illness is very contagious, adults not immunized are at high risk of be infected. Since the third part of the immunocompromised patients infected have a disseminated herpes zoster disease[69], it should be recommended the confirmation of the seroproteccion of IBD patients before the administration of an immunomodulator.

Local guidelines generally recommend the vaccination in children of an age between 12 and 18 mo, and the administration of a booster dose at 11-12 years. Children with IBD not treated with immunosuppressant drugs should follow the same vaccination protocol[2]. In the case of adult patients with IBD not immunized against varicella, it is recommended the administration of 2-dose series of varicella vaccine at least 3 wk before starting any immunomodulatory therapy[2]. Although recent studies show that this vaccine is as effective as save, even in immunosuppressed patients, data are still scarce. Given the potential risk of complications due to the progression of the infection in immunocompromised adults, the benefits and risks of the varicella vaccine should be considered on an individual basis.

After the varicella infection, the virus stays latent within the spinal ganglion. The reactivation of the virus results in the Herpes zoster infection (shingles), that is developed in up to 1 in 3 people in the general population, and in an higher rate among immunocompromised patients[69].

An herpes zoster vaccine has been licensed in the United States. This vaccine is a live-attenuated strain of the varicella zoster virus, 14 times more potent than the single-antigen varicella vaccine, and it is suggested for people over 60 years in order to prevent and/or reduce the severity of herpes zoster complications[70]. As little information is available regarding the safety and efficacy the vaccine in immunocompromised patients, and immunosuppression can lead to a disseminated disease in case of infection, guidelines do not recommend the administration of the shingles vaccine in patients treated with anti-TNF drugs[71] and suggests a window of 1-3 mo after initiating immunosuppressive therapy[72-74]. Nevertheless, the Centres of Disease Control (CDC) and the Advisory Committee on immunization Practices (ACIP) stated that patients with lower levels of immunosuppression (≤ 0.4 mg/kg per week of methotrexate, ≤ 3 mg/kg per day of azathioprine, or ≤ 1.5 mg/kg per day of mercaptopurine) can tolerate attenuated herpes zoster–based vaccine. In fact, the risk of recurrence of varicella is low, even in profoundly immunosuppressed patients, as varicella-zoster immunity is well-maintained over time[71].

In this respect, Zhang *et al*[72] studied the incidence of herpes zoster disease after administering the live-attenuated vaccine in a cohort of 450000 patients with immune-mediated diseases (including IBD). The study concluded that the short-term risk of herpes zoster was not increased in vaccinated patients, independently of the prescription of anti-TNF therapy. Moreover, a decline in the incidence of herpes zoster over a median 2 years of follow-up was related to the vaccination[72]. However, the proportion of vaccinated patients was small (1.2%), suggesting that further evidence is needed to confirm the safety of the vaccine in this population.

**CONCLUSION**

Patients with IBD are at risk of vaccine-preventable illnesses. The immunization status of patients with IBD should be verified, even with respect to routinely administered vaccines. It has been suggested that the response to vaccines in IBD patients is impaired owing to the immunological alterations generated by the disease and also to the immunomodulatory treatments. The immunogenicity of hepatitis B, influenza, and pneumococcal vaccines is impaired in IBD patients, whereas the response to papillomavirus vaccine seems to be similar to that observed in the healthy population. Data on the immunogenicity of tetanus vaccine in patients with IBD are conflicting. Studies assessing the response of patients with IBD to measles-mumps-rubella, varicella and herpes zoster vaccines are scarce. The mechanisms involved in the altered response to vaccines in IBD patients remain unclear. Several HLA haplotypes have been associated with a higher risk of vaccination failure; however, whether these genetic factors cause deficient antigen presentation or diminished recognition by immune cells remains unknown.

Studies aiming to assess the response to vaccines in IBD patients and to identify the mechanisms involved in their immunogenicity are warranted. Understanding the alterations of the immune system of IBD patients is a key area in the development of more immunogenic vaccines for this particular group of patients and for other patients with immune-mediated diseases.

**REFERENCES**

1 **Viget N**, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. *Gut* 2008; **57**: 549-558 [PMID: 18178610 DOI: 10.1136/gut.2006.114660]

2 **Rahier JF**, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, Doherty G, Ehehalt R, Esteve M, Katsanos K, Lees CW, Macmahon E, Moreels T, Reinisch W, Tilg H, Tremblay L, Veereman-Wauters G, Viget N, Yazdanpanah Y, Eliakim R, Colombel JF. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. *J Crohns Colitis* 2014; **8**: 443-468 [PMID: 24613021 DOI: 10.1016/j.crohns.2013.12.013]

3 **Wasan SK**, Coukos JA, Farraye FA. Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge. *Inflamm Bowel Dis* 2011; **17**: 2536-2540 [PMID: 21538710 DOI: 10.1002/ibd.21667]

4 **Crawford NW**, Catto-Smith AG, Oliver MR, Cameron DJ, Buttery JP. An Australian audit of vaccination status in children and adolescents with inflammatory bowel disease. *BMC Gastroenterol* 2011; **11**: 87 [PMID: 21798078 DOI: 10.1186/1471-230X-11-87]

5 **Teich N**, Klugmann T, Tiedemann A, Holler B, Mössner J, Liebetrau A, Schiefke I. Vaccination coverage in immunosuppressed patients: results of a regional health services research study. *Dtsch Arztebl Int* 2011; **108**: 105-111 [PMID: 21412507 DOI: 10.3238/arztebl.2011.0105]

6 **Altunöz ME**, Senateş E, Yeşil A, Calhan T, Ovünç AO. Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls. *Dig Dis Sci* 2012; **57**: 1039-1044 [PMID: 22147248 DOI: 10.1007/s10620-011-1980-8]

7 **Mamula P**, Markowitz JE, Piccoli DA, Klimov A, Cohen L, Baldassano RN. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2007; **5**: 851-856 [PMID: 17544875 DOI: 10.1016/j.cgh.2007.02.035]

8 **deBruyn JC**, Hilsden R, Fonseca K, Russell ML, Kaplan GG, Vanderkooi O, Wrobel I. Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease. *Inflamm Bowel Dis* 2012; **18**: 25-33 [PMID: 21472826 DOI: 10.1002/ibd.21706]

9 **Melmed GY**, Agarwal N, Frenck RW, Ippoliti AF, Ibanez P, Papadakis KA, Simpson P, Barolet-Garcia C, Ward J, Targan SR, Vasiliauskas EA. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. *Am J Gastroenterol* 2010; **105**: 148-154 [PMID: 19755964 DOI: 10.1038/ajg.2009.523]

10 **Fiorino G**, Peyrin-Biroulet L, Naccarato P, Szabò H, Sociale OR, Vetrano S, Fries W, Montanelli A, Repici A, Malesci A, Danese S. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. *Inflamm Bowel Dis* 2012; **18**: 1042-1047 [PMID: 21674732 DOI: 10.1002/ibd.21800]

11 **Gisbert JP**, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2011; **33**: 619-633 [PMID: 21416659 DOI: 10.1111/j.1365-2036.2010.04570.x]

12 **Loras C**, Gisbert JP, Mínguez M, Merino O, Bujanda L, Saro C, Domenech E, Barrio J, Andreu M, Ordás I, Vida L, Bastida G, González-Huix F, Piqueras M, Ginard D, Calvet X, Gutiérrez A, Abad A, Torres M, Panés J, Chaparro M, Pascual I, Rodriguez-Carballeira M, Fernández-Bañares F, Viver JM, Esteve M. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. *Gut* 2010; **59**: 1340-1346 [PMID: 20577000 DOI: 10.1136/gut.2010.208413]

13 **Melmed GY**. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. *Inflamm Bowel Dis* 2009; **15**: 1410-1416 [PMID: 19462435 DOI: 10.1002/ibd.20943]

14 **Wasan SK**, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. *Am J Gastroenterol* 2010; **105**: 1231-1238 [PMID: 20104218 DOI: 10.1038/ajg.2009.733]

15 **Coates T**, Wilson R, Patrick G, André F, Watson V. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. *Clin Ther* 2001; **23**: 392-403 [PMID: 11318074]

16 **Sands BE**, Cuffari C, Katz J, Kugathasan S, Onken J, Vitek C, Orenstein W. Guidelines for immunizations in patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2004; **10**: 677-692 [PMID: 15472534]

17 **Mast EE**, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, Rodewald LE, Douglas JM, Janssen RS, Ward JW. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. *MMWR Recomm Rep* 2006; **55**: 1-33; quiz CE1-4 [PMID: 17159833]

18 **Melmed GY**, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, Frenck RW, Targan SR, Vasiliauskas EA. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. *Am J Gastroenterol* 2006; **101**: 1834-1840 [PMID: 16817843 DOI: 10.1111/j.1572-0241.2006.00646.x]

19 **Vida Pérez L**, Gómez Camacho F, García Sánchez V, Iglesias Flores EM, Castillo Molina L, Cerezo Ruiz A, Casáis Juanena L, De Dios Vega JF. [Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease]. *Med Clin (Barc)* 2009; **132**: 331-335 [PMID: 19268981 DOI: 10.1016/j.medcli.2008.07.013]

20 **Gisbert JP**, Villagrasa JR, Rodríguez-Nogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. *Am J Gastroenterol* 2012; **107**: 1460-1466 [PMID: 23034605 DOI: 10.1038/ajg.2012.79]

21 **Loras C**, Gisbert JP, Saro MC, Piqueras M, Sánchez-Montes C, Barrio J, Ordás I, Montserrat A, Ferreiro R, Zabana Y, Chaparro M, Fernández-Bañares F, Esteve M. Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3). *J Crohns Colitis* 2014; **8**: 1529-1538 [PMID: 25052345 DOI: 10.1016/j.crohns.2014.06.009]

22 **Gisbert JP**, Menchén L, García-Sánchez V, Marín I, Villagrasa JR, Chaparro M. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2012; **35**: 1379-1385 [PMID: 22530631 DOI: 10.1111/j.1365-2036.2012.05110.x]

23 **Chaparro M**, Gordillo J, Domenech E, Esteve M, Barreiro de-Acosta M, Villoria A, Iglesias-Flores E, Blasi M, Naves JE, Benitez O, Nieto L, Calvet X, Garcia-Sanchez V, Villagrasa JR, Marin AC, Ramas M, Moreno I, Gisbert JP. Prospective, randomized clinical trial comparing the efficacy of two vaccines against hepatitis B virus (HBV) in inflammatory bowel disease (IBD) patients. *J Crohns Colitis* 2015; **9** (Suppl.1): S299 [DOI: 10.1093/ecco-jcc/jju027.557]

24 **Banatvala JE**, Van Damme P. Hepatitis B vaccine -- do we need boosters? *J Viral Hepat* 2003; **10**: 1-6 [PMID: 12558904]

25 **Hollinger FB**. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. *Am J Med* 1989; **87**: 36S-40S [PMID: 2528297 DOI: 10.1016/0002-9343(89)90530-5]

26 **Jafarzadeh A**, Bagheri-Jamebozorgi M, Nemati M, Golsaz-Shirazi F, Shokri F. eukocyte Antigens Influence the Antibody Response to Hepatitis B Vaccine. *Iran J Allergy Asthma Immunol* 2015; In press

27 **Chedid MG**, Deulofeut H, Yunis DE, Lara-Marquez ML, Salazar M, Deulofeut R, Awdeh Z, Alper CA, Yunis EJ. Defect in Th1-like cells of nonresponders to hepatitis B vaccine. *Hum Immunol* 1997; **58**: 42-51 [PMID: 9438208]

28 **Shokrgozar MA**, Shokri F. Enumeration of hepatitis B surface antigen-specific B lymphocytes in responder and non-responder normal individuals vaccinated with recombinant hepatitis B surface antigen. *Immunology* 2001; **104**: 75-79 [PMID: 11576223]

29 **Weihrauch MR**, von Bergwelt-Baildon M, Kandic M, Weskott M, Klamp W, Rosler J, Schultze JL. T cell responses to hepatitis B surface antigen are detectable in non-vaccinated individuals. *World J Gastroenterol* 2008; **14**: 2529-2533 [PMID: 18442200 DOI: 10.3748/wjg.14.2529]

30 **Suzuki T**, Yamauchi K, Kuwata T, Hayashi N. Characterization of hepatitis B virus surface antigen-specific CD4+ T cells in hepatitis B vaccine non-responders. *J Gastroenterol Hepatol* 2001; **16**: 898-903 [PMID: 11555104]

31 **Li J**, Tan D, Liu H, Li K. CD4(+) CD25(+) FoxP3(+) T regulatory cells in subjects responsive or unresponsive to hepatitis B vaccination. *Zhong Nan Da Xue Xue Bao Yi Xue Ban* 2011; **36**: 1046-1051 [PMID: 22169715 DOI: 10.3969/j.issn.1672-7347.2011.11.003]

32 **Albarran B**, Goncalves L, Salmen S, Borges L, Fields H, Soyano A, Montes H, Berrueta L. Profiles of NK, NKT cell activation and cytokine production following vaccination against hepatitis B. *APMIS* 2005; **113**: 526-535 [PMID: 16086823 DOI: 10.1111/j.1600-0463.2005.apm\_191.x]

33 **Yao ZQ**, Moorman JP. Immune exhaustion and immune senescence: two distinct pathways for HBV vaccine failure during HCV and/or HIV infection. *Arch Immunol Ther Exp (Warsz)* 2013; **61**: 193-201 [PMID: 23400275 DOI: 10.1007/s00005-013-0219-0]

34 **Litjens NH**, Huisman M, van den Dorpel M, Betjes MG. Impaired immune responses and antigen-specific memory CD4+ T cells in hemodialysis patients. *J Am Soc Nephrol* 2008; **19**: 1483-1490 [PMID: 18480314 DOI: 10.1681/ASN.2007090971]

35 **Armstrong KE**, Bush HM, Collins JD, Feola DJ, Caldwell GC, Thornton AC. Role of CD4 count in immunity development after hepatitis A and B vaccination among HIV-infected patients: Kentucky, 2002-2007. *J Int Assoc Physicians AIDS Care (Chic)* 2010; **9**: 179-186 [PMID: 20530473 DOI: 10.1177/1545109710368721]

36 **Sari F**, Taskapan H. Good response to HBsAg vaccine in dialysis patients is associated with high CD4+/CD8+ ratio. *Int Urol Nephrol* 2012; **44**: 1501-1506 [PMID: 21809071 DOI: 10.1007/s11255-011-0043-6]

37 **Cho JH**, Brant SR. Recent insights into the genetics of inflammatory bowel disease. *Gastroenterology* 2011; **140**: 1704-1712 [PMID: 21530736 DOI: 10.1053/j.gastro.2011.02.046]

38 **Franke A**, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Cohen A, Colombel JF, Cottone M, Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Gearry R, Glas J, Van Gossum A, Guthery SL, Halfvarson J, Verspaget HW, Hugot JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, Mowat C, Newman W, Panés J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers PC, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, D'Amato M, Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ, Parkes M. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. *Nat Genet* 2010; **42**: 1118-1125 [PMID: 21102463 DOI: 10.1038/ng.717]

39 **Muñoz N**. Human papillomavirus and cancer: the epidemiological evidence. *J Clin Virol* 2000; **19**: 1-5 [PMID: 11091143]

40 **Nowak Z**, Karowicz-Bilińska A. [Human papilloma virus infection in pregnant women with normal pap-smears, HPV oncogenity and risk factors]. *Ginekol Pol* 2007; **78**: 678-684 [PMID: 18159820]

41 **Muñoz N**, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. *N Engl J Med* 2003; **348**: 518-527 [PMID: 12571259 DOI: 10.1056/NEJMoa021641348/6/518]

42 **Harper DM**, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. *Lancet* 2006; **367**: 1247-1255 [PMID: 16631880 DOI: 10.1016/S0140-6736(06)68439-0]

43 **Villa LL**, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. *Lancet Oncol* 2005; **6**: 271-278 [PMID: 15863374 DOI: 10.1016/S1470-2045(05)70101-7]

44 **Jacobson DL**, Bousvaros A, Ashworth L, Carey R, Shrier LA, Burchett SK, Renna H, Lu Y. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. *Inflamm Bowel Dis* 2013; **19**: 1441-1449 [PMID: 23567780 DOI: 10.1097/MIB.0b013e318281341b]

45 **Schanzer DL**, Langley JM, Tam TW. Role of influenza and other respiratory viruses in admissions of adults to Canadian hospitals. *Influenza Other Respir Viruses* 2008; **2**: 1-8 [PMID: 19453488 DOI: 10.1111/j.1750-2659.2008.00035.x]

46 **Schanzer DL**, Langley JM, Tam TW. Hospitalization attributable to influenza and other viral respiratory illnesses in Canadian children. *Pediatr Infect Dis J* 2006; **25**: 795-800 [PMID: 16940836 DOI: 10.1097/01.inf.0000232632.86800.8c00006454-200609000-00008]

47 **Billings JL**, Hertz MI, Savik K, Wendt CH. Respiratory viruses and chronic rejection in lung transplant recipients. *J Heart Lung Transplant* 2002; **21**: 559-566 [PMID: 11983546]

48 **Hassan IA**, Chopra R, Swindell R, Mutton KJ. Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: the Christie hospital experience. *Bone Marrow Transplant* 2003; **32**: 73-77 [PMID: 12815481 DOI: 10.1038/sj.bmt.1704048]

49 **Fiore AE**, Shay DK, Haber P, Iskander JK, Uyeki TM, Mootrey G, Bresee JS, Cox NJ. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. *MMWR Recomm Rep* 2007; **56**: 1-54 [PMID: 17625497]

50 **Lu Y**, Jacobson DL, Ashworth LA, Grand RJ, Meyer AL, McNeal MM, Gregas MC, Burchett SK, Bousvaros A. Immune response to influenza vaccine in children with inflammatory bowel disease. *Am J Gastroenterol* 2009; **104**: 444-453 [PMID: 19174786 DOI: 10.1038/ajg.2008.120]

51 **Gelinck LB**, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, Rimmelzwaan GF, Kroon FP. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. *Ann Rheum Dis* 2008; **67**: 713-716 [PMID: 17965123 DOI: 10.1136/ard.2007.077552]

52 **Cowan M**, Chon WJ, Desai A, Andrews S, Bai Y, Veguilla V, Katz JM, Josephson MA, Wilson PC, Sciammas R, Chong AS. Impact of immunosuppression on recall immune responses to influenza vaccination in stable renal transplant recipients. *Transplantation* 2014; **97**: 846-853 [PMID: 24366008 DOI: 10.1097/01.TP.0000438024.10375.2d]

53 **Bálint A**, Farkas K, Éva PK, Terhes G, Urbán E, Szucs M, Nyári T, Bata Z, Nagy F, Szepes Z, Miheller P, Lorinczy K, Lakatos PL, Lovász B, Tamás S, Kulcsár A, Berényi A, Törocsik D, Daróczi T, Saródi Z, Wittmann T, Molnár T. Antibody and cell-mediated immune response to whole virion and split virion influenza vaccine in patients with inflammatory bowel disease on maintenance immunosuppressive and biological therapy. *Scand J Gastroenterol* 2015; **50**: 174-181 [PMID: 25384624 DOI: 10.3109/00365521.2014.928902]

54 **Poland GA**, Ovsyannikova IG, Jacobson RM. Immunogenetics of seasonal influenza vaccine response. *Vaccine* 2008; **26** Suppl 4: D35-D40 [PMID: 19230157 DOI: 10.1016/j.vaccine.2008.07.065]

55 **Targonski PV**, Poland GA. Pneumococcal vaccination in adults: recommendations, trends, and prospects. *Cleve Clin J Med* 2007; **74**: 401-46, 401-46, 401-46, [PMID: 17569198]

56 **Leggat DJ**, Khaskhely NM, Iyer AS, Mosakowski J, Thompson RS, Weinandy JD, Westerink MA. Pneumococcal polysaccharide vaccination induces polysaccharide-specific B cells in adult peripheral blood expressing CD19⁺CD20⁺CD3⁻CD70⁻CD27⁺IgM⁺CD43⁺CD5⁺/⁻. *Vaccine* 2013; **31**: 4632-4640 [PMID: 23911852 DOI: 10.1016/j.vaccine.2013.07.030]

57 **Leggat DJ**, Thompson RS, Khaskhely NM, Iyer AS, Westerink MA. The immune response to pneumococcal polysaccharides 14 and 23F among elderly individuals consists predominantly of switched memory B cells. *J Infect Dis* 2013; **208**: 101-108 [PMID: 23547142 DOI: 10.1093/infdis/jit139]

58 **Kruetzmann S**, Rosado MM, Weber H, Germing U, Tournilhac O, Peter HH, Berner R, Peters A, Boehm T, Plebani A, Quinti I, Carsetti R. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. *J Exp Med* 2003; **197**: 939-945 [PMID: 12682112 DOI: 10.1084/jem.20022020]

59 **Carsetti R**, Rosado MM, Donnanno S, Guazzi V, Soresina A, Meini A, Plebani A, Aiuti F, Quinti I. The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency. *J Allergy Clin Immunol* 2005; **115**: 412-417 [PMID: 15696104 DOI: 10.1016/j.jaci.2004.10.048]

60 **Di Sabatino A**, Carsetti R, Rosado MM, Ciccocioppo R, Cazzola P, Morera R, Tinozzi FP, Tinozzi S, Corazza GR. Immunoglobulin M memory B cell decrease in inflammatory bowel disease. *Eur Rev Med Pharmacol Sci* 2004; **8**: 199-203 [PMID: 15638230]

61 **Di Sabatino A**, Rosado MM, Ciccocioppo R, Cazzola P, Morera R, Corazza GR, Carsetti R. Depletion of immunoglobulin M memory B cells is associated with splenic hypofunction in inflammatory bowel disease. *Am J Gastroenterol* 2005; **100**: 1788-1795 [PMID: 16086716 DOI: 10.1111/j.1572-0241.2005.41939.x]

62 **Fallahi G**, Aghamohammadi A, Khodadad A, Hashemi M, Mohammadinejad P, Asgarian-Omran H, Najafi M, Farhmand F, Motamed F, Soleimani K, Soheili H, Parvaneh N, Darabi B, Nasiri Kalmarzi R, Pourhamdi S, Abolhassani H, Mirminachi B, Rezaei N. Evaluation of antibody response to polysaccharide vaccine and switched memory B cells in pediatric patients with inflammatory bowel disease. *Gut Liver* 2014; **8**: 24-28 [PMID: 24516697 DOI: 10.5009/gnl.2014.8.1.24]

63 **Di Sabatino A**, Rosado MM, Cazzola P, Biancheri P, Tinozzi FP, Laera MR, Cantoro L, Vanoli A, Carsetti R, Corazza GR. Splenic function and IgM-memory B cells in Crohn's disease patients treated with infliximab. *Inflamm Bowel Dis* 2008; **14**: 591-596 [PMID: 18240280 DOI: 10.1002/ibd.20374]

64 **Salinas GF**, De Rycke L, Barendregt B, Paramarta JE, Hreggvidstdottir H, Cantaert T, van der Burg M, Tak PP, Baeten D. Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. *Ann Rheum Dis* 2013; **72**: 1037-1043 [PMID: 22968102]

65 **Brogan MD**, Shanahan F, Oliver M, Stevens RH, Targan SR. Defective memory B cell formation in patients with inflammatory bowel disease following tetanus toxoid booster immunization. *J Clin Lab Immunol* 1987; **24**: 69-74 [PMID: 3437440]

66 **Stevens R**, Oliver M, Brogan M, Heiserodt J, Targan S. Defective generation of tetanus-specific antibody-producing B cells after in vivo immunization of Crohn's disease and ulcerative colitis patients. *Gastroenterology* 1985; **88**: 1860-1866 [PMID: 3873371]

67 **Nielsen HJ**, Mortensen T, Holten-Andersen M, Brünner N, Sørensen S, Rask-Madsen J. Increased levels of specific leukocyte- and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease. *Scand J Gastroenterol* 2001; **36**: 265-269 [PMID: 11305513]

68 **Bernstein CN**, Rawsthorne P, Blanchard JF. Population-based case-control study of measles, mumps, and rubella and inflammatory bowel disease. *Inflamm Bowel Dis* 2007; **13**: 759-762 [PMID: 17230540 DOI: 10.1002/ibd.20089]

69 **Marin M**, Güris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2007; **56**: 1-40 [PMID: 17585291]

70 **Oxman MN**, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. *N Engl J Med* 2005; **352**: 2271-2284 [PMID: 15930418 DOI: 10.1056/NEJMoa051016]

71 **Harpaz R**, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2008; **57**: 1-30; quiz CE2-4 [PMID: 18528318]

72 **Zhang J**, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, Saag KG, Baddley JW, Curtis JR. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. *JAMA* 2012; **308**: 43-49 [PMID: 22760290]

73 **Kotton CN**. Nailing down the shingles in IBD. *Inflamm Bowel Dis* 2007; **13**: 1178-1179 [PMID: 17476676 DOI: 10.1002/ibd.20161]

74 **Singh A**, Englund K. Q: Who should receive the shingles vaccine? *Cleve Clin J Med* 2009; **76**: 45-48 [PMID: 19122110 DOI: 10.3949/ccjm.75a.08046]

**P-Reviewer:** Miheller p **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Table 1 Vaccines recommended in patients with inflammatory bowel disease**

|  |  |  |  |
| --- | --- | --- | --- |
| **Vaccine** | **Type of immunogen** | **General recommendations for vaccination in IBD** | **Concerns in IBD patients on immunosuppressive therapy** |
| **HBV** | Recombinant protein | After checking the serological status for HBV: double-dose schedule | None |
| **HPV1** | Quadrivalent vaccine  (Recombinant proteins) | Women aged between 11-12 yr: 3 doses (0, 2 and 6 mo) | None |
| **Influenza** | Inactivated virus | 1 dose annually | None |
| **Pneumococcus** | Polysaccharides, conju-gated or not to a protein carrier | 1 dose every 5 yr | None |
| **Tetanus** | Inactivated toxoid | * Patient previously vaccinated: 1 dose every 10 years * Unknown or not previously vaccinated: 3-doses | None |
| **Measles-mumps-rubella** | Live attenuated virus | Non-immunized: Standard schedule | Contraindicated |
| **Varicella** | Live attenuated virus | Non-immunized: 2 doses (0 and 1-2 mo) | Risks and benefits should be evaluated on an individual basis |
| **Herpes zoster1** | Live attenuated virus | Patients aged over 60 yr: Standard schedule | Risks and benefits should be evaluated on an individual basis |

1Depending on local recommendations. Source: Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease[2]. HBV: Hepatitis B virus; HPV: Human papillomavirus.

**Table 2 Vaccines recommended in patients with inflammatory bowel disease and mechanisms associated with impaired response in these patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Vaccine** | **Immunogen** | **Impaired response** | **Factors associated with a lower response** | **Mechanisms associated with lower immunogenicity** |
| **HBV** | Recombinant protein | Yes | Age[20,21,23], immunosuppressive or anti-TNF therapy[20,21,23] | Not described |
| **HPV** | Recombinant protein | No | - | - |
| **Influenza** | Inactivated virus | Yes | Immunosuppressive therapy[8] | Not described |
| **Pneumococcus** | Polysaccharides | Yes | Immunosuppressive and/or anti-TNF therapy[9,10,55] | Conflicting results about memory B cells[60,62] |
| **Tetanus** | Inactivated toxoid | Unclear | None described | Defects in the development of IgG-secreting plasma cells[65] |
| **Measles-mump-rubella** | Live attenuated virus | No | - | - |
| **Varicella** | Live attenuated virus | No | - | - |
| **Herpes zoster** | Live attenuated virus | No | - | - |

HBV: Hepatitis B virus; HPV: Human papillomavirus; TNF: tumor necrosis factor.